2023
Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis
Li X, Li Y, Xiao J, Wang H, Guo Y, Mao X, Shi P, Hou Y, Zhang X, Zhao N, Zheng M, He Y, Ding J, Tan Y, Liao M, Li L, Peng Y, Li X, Pan Q, Xie Q, Li Q, Li J, Li Y, Chen Z, Huang Y, Assis D, Cai S, Boyer J, Huang X, Tang C, Liu X, Peng S, Chai J. Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis. Nature Communications 2023, 14: 29. PMID: 36759512, PMCID: PMC9911648, DOI: 10.1038/s41467-022-34606-w.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisPrimary biliary cholangitis patientsBiliary cholangitisEtiology of primary biliary cholangitisScRNA-seqPathogenic targetsSeverity of diseaseSingle-cell RNA sequencingAMA-M2PBC patientsAutoantibody levelsPolymeric immunoglobulin receptorMemory BMultiplex immunofluorescenceCholangiocyte injuryPlasma cellsAutoimmune diseasesRNAscope analysisCholangiocytesImmunoglobulin receptorBile formationPatientsTherapeutic interventionsMultiplexed IFRNA sequencing
2021
Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine
Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.Peer-Reviewed Original ResearchConceptsHuman cholestatic diseasesCholestatic diseaseBiliary organoidsStudy of pathophysiologyCholestasis ResearchBiliary treeDisease stageIndividual patientsTranslational studiesPrimary cholangiocytesPersonalized approachBiliary tissueApplication of organoidsStandardization of terminologyTranslational medicineDiseaseOrganoidsMedicineOrganoid technologyPatientsPathophysiology
2020
AS055 Co-culture of bile-derived organoids from primary sclerosing cholangitis patients with CD4+ T cells replicates pathogenic, CCL20 dependent biliary-immune interactions
Soroka C, Roberts S, Hohenester S, Boyer J, Assis D. AS055 Co-culture of bile-derived organoids from primary sclerosing cholangitis patients with CD4+ T cells replicates pathogenic, CCL20 dependent biliary-immune interactions. Journal Of Hepatology 2020, 73: s41. DOI: 10.1016/s0168-8278(20)30634-6.Peer-Reviewed Original Research
2019
Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies
Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.BooksConceptsPrimary sclerosing cholangitisPrimary sclerosing cholangitis patientsEndoscopic retrograde cholangiopancreatographySclerosing cholangitisCholangitis patientsRetrograde cholangiopancreatographyExtrahepatic bile duct epitheliumTherapeutic endoscopic retrograde cholangiopancreatographyChemo/cytokinesEnd-stage diseaseBile duct epitheliumPatient-derived organoidsPharmacotherapeutic treatmentClinical indicationsIndividual patientsInflammatory stimuliHeterogeneous diseaseBiliary phenotypeDuct epitheliumDisease statusCholangitisCholangiopathyHuman bileBiliary cellsPatients
2017
Mechanisms of bile acid mediated inflammation in the liver
Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Molecular Aspects Of Medicine 2017, 56: 45-53. PMID: 28606651, PMCID: PMC5662014, DOI: 10.1016/j.mam.2017.06.001.Peer-Reviewed Original ResearchConceptsLiver injuryBile acidsCholestatic animal modelsCauses of cholestasisCholestatic liver injuryInnate immune cellsBiliary injuryNeutrophil recruitmentBile flowImmune cellsEffective therapyInflammatory responseAnimal modelsMolecular mediatorsCholestasisInjuryNovel targetLiverElevated levelsPathological processesMolecular mechanismsHepatocytesInflammationPatientsPathogenesis
2015
Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis
Chai J, Cai SY, Liu X, Lian W, Chen S, Zhang L, Feng X, Cheng Y, He X, He Y, Chen L, Wang R, Wang H, Boyer JL, Chen W. Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis. Journal Of Hepatology 2015, 63: 1440-1448. PMID: 26212029, PMCID: PMC4686151, DOI: 10.1016/j.jhep.2015.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultBile CanaliculiCase-Control StudiesCholestasisCytoskeletal ProteinsFemaleGallstonesGene Knockdown TechniquesHep G2 CellsHumansLiverMaleMembrane ProteinsMiddle AgedModels, BiologicalMultidrug Resistance-Associated Protein 2Multidrug Resistance-Associated ProteinsPhosphorylationProtein Kinase CReceptors, Autocrine Motility FactorRNA, MessengerThreonineConceptsObstructive cholestasisCholestatic liverMRP2 expressionMrp2 internalizationHepG2 cellsHuman obstructive cholestasisMRP2 protein expressionMembrane expressionHepatic MRP2 expressionNon-cholestatic controlsExpression of PKCαTotal protein levelsBile ductCholestatic patientsCholestasisBile acidsPatientsAbstractTextHuman liverProtein expressionProtein levelsLiverMRP2JaundiceAIMS
2013
The role of macrophage migration inhibitory factor in autoimmune liver disease
Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkersBiopsyCase-Control StudiesCohort StudiesFemaleGene FrequencyHepatitis, AutoimmuneHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesLiverLiver Cirrhosis, BiliaryMacrophage Migration-Inhibitory FactorsMaleMicrosatellite RepeatsMiddle AgedPhenotypePolymorphism, Single NucleotideConceptsMacrophage migration inhibitory factorPrimary biliary cirrhosisAutoimmune hepatitisMigration inhibitory factorMIF receptorHealthy controlsInhibitory factorAutoimmune liver diseaseMIF promoter polymorphismsHepatic stellate cellsEnzyme-linked immunosorbentCATT7 alleleImmunopathogenic basisMIF expressionMIF locusBiliary cirrhosisLiver diseaseInflammatory phenotypeReceptor profileStellate cellsPromoter polymorphismPatientsSerum samplesCD74Single nucleotide polymorphisms
1999
The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis
Combes B, Markin R, Wheeler D, Rubin R, West A, Mills A, Eigenbrodt E, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Carithers R. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999, 30: 602-605. PMID: 10462363, PMCID: PMC3935822, DOI: 10.1002/hep.510300315.Peer-Reviewed Original ResearchConceptsFlorid duct lesionsPrimary biliary cirrhosisBile duct destructionDuct lesionsUrsodeoxycholic acidDuct destructionBiliary cirrhosisPlacebo-controlled trialNeedle biopsy specimensUDCA patientsAdvanced diseasePlacebo medicationEarly diseaseBiopsy specimensPatientsLesionsBeneficial effectsPathology literaturePrevalenceCirrhosisPlaceboMedicationsDiseaseYearsHepatopathologistBiliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid
Combes B, Carithers R, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Risser R, Rossi S, Hofmann A. Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1999, 29: 1649-1654. PMID: 10347103, PMCID: PMC4004074, DOI: 10.1002/hep.510290618.Peer-Reviewed Original ResearchMeSH KeywordsBileBile Acids and SaltsChenodeoxycholic AcidCholic AcidChromatography, GasChromatography, High Pressure LiquidDeoxycholic AcidDouble-Blind MethodDrug Administration ScheduleFemaleHumansLithocholic AcidLiver Cirrhosis, BiliaryMaleMiddle AgedPlacebosRegression AnalysisReproducibility of ResultsTime FactorsUrsodeoxycholic AcidConceptsPrimary biliary cirrhosisBile acid compositionUrsodeoxycholic acidBile acidsBiliary cirrhosisSeverity of PBCSingle bedtime dosePlacebo-controlled trialBiliary bile acidsEndogenous bile acidsMajor bile acidsBedtime dosePlacebo medicationDuodenal bileHigh-pressure liquid chromatography methodPatientsNormal personsBileSignificant decreaseCirrhosisAcid compositionCDCATaurineLiquid chromatography methodYears
1995
A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisStratum 1Advanced primary biliary cirrhosisPlacebo-controlled trialBile acid poolLiver histologyPrognostic factorsTreatment failureSingle doseUrsodeoxycholic acidSevere symptomsPatientsUrsodiolLaboratory testsPlaceboHistologyBilirubinCirrhosisBiochemical testsGood responseStratum 3Acid poolLess effectA randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, Mcdonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. DOI: 10.1016/0270-9139(95)90294-5.Peer-Reviewed Original ResearchPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisMajor complicationsStratum 1Liver diseaseTreatment failureAdvanced primary biliary cirrhosisPlacebo-treated patientsPlacebo-controlled trialBile acid poolStratum 3Advanced diseaseLiver histologyPrognostic factorsMilder diseaseSingle doseUrsodeoxycholic acidUrsodiolSevere symptomsPatientsPlaceboLaboratory testsComplicationsBilirubin
1994
Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years
Mahl T, Shockcor W, Boyer J. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. Journal Of Hepatology 1994, 20: 707-713. PMID: 7930469, DOI: 10.1016/s0168-8278(05)80139-4.Peer-Reviewed Original ResearchConceptsTime of diagnosisAsymptomatic patientsSurvival of patientsGender-matched control populationPrimary biliary cirrhosisMedian followElevated bilirubinOverall survivalSymptomatic patientsAdvanced fibrosisBile stasisBiliary cirrhosisIndependent predictorsLiver biopsyLiver diseaseDiminished survivalLarge cohortPatientsOriginal diagnosisAccurate followControl populationSymptomsSurvival dataDiagnosisSurvival
1985
Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history
Beswick D, Klatskin G, Boyer J. Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history. Gastroenterology 1985, 89: 267-271. PMID: 4007417, DOI: 10.1016/0016-5085(85)90325-7.Peer-Reviewed Original ResearchConceptsAsymptomatic primary biliary cirrhosisPrimary biliary cirrhosisBiliary cirrhosisAsymptomatic stateGeneral populationInitial liver biopsySubgroup of patientsLife table survival analysisDevelopment of symptomsMedian followPortal granulomasOverall survivalProgressive diseaseLiver biopsyLiver diseaseMedian periodAutoimmune disordersExtended followHistologic featuresBenign outcomeCirrhosisPatientsSurvival analysisNatural historySymptoms
1983
The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis
Roll J, Boyer J, Barry D, Klatskin G. The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis. New England Journal Of Medicine 1983, 308: 1-7. PMID: 6847917, DOI: 10.1056/nejm198301063080101.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisBiliary cirrhosisPoor prognosisSymptomatic primary biliary cirrhosisOnset of diseaseAsymptomatic patientsAsymptomatic diseaseClinical featuresHistologic featuresHistologic stagePrediction of riskPrognostic importanceSerum bilirubinHepatic fibrosisHistologic findingsPortal areasProlonged survivalMultivariate analysisPatientsControl populationPrognosisWeight lossElevated levelsLife expectancySurvival data
1980
Aminopyrine n-Demethylation: A Prognostic test of liver function in patients with alcoholic liver disease
Schneider J, Baker A, Haines N, Hatfield G, Boyer J. Aminopyrine n-Demethylation: A Prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980, 79: 1145-1150. PMID: 6777231, DOI: 10.1016/0016-5085(80)90906-3.Peer-Reviewed Original ResearchConceptsAminopyrine breath testAlcoholic liver diseaseBreath testLiver diseaseAlcoholic hepatitisClinical improvementHistologic severityLiver functionConventional liver function testsLiver function testsGroup of patientsShort-term survivalClinical featuresFunction testsHistologic confirmationClinical statusProthrombin timePatientsPrognostic testDiseaseHepatitisSeveritySurvivalSGPTSGOTBone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D
Reed J, Meredith S, Nemchausky B, Rosenberg I, Boyer J. Bone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1980, 78: 512-517. PMID: 7351289, DOI: 10.1016/0016-5085(80)90865-3.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisBiliary cirrhosisBone biopsyBone diseaseIliac crest bone biopsiesMineralized bone massVitamin D deficiencyRelative osteoid volumeCrest bone biopsiesTrabecular bone volumeLow serum concentrationsD deficiencyD therapySerum concentrationsOsteoid volumeBone massTreatment periodOsteoid surfaceBone volumeOsteomalaciaHistomorphometric analysisCirrhosisPatientsBone mineralizationBiopsy
1979
Liver Failure With Steatonecrosis After Jejunoileal Bypass: Recovery With Parenteral Nutrition and Reanastomosis
Baker A, Elson C, Jaspan J, Boyer J. Liver Failure With Steatonecrosis After Jejunoileal Bypass: Recovery With Parenteral Nutrition and Reanastomosis. JAMA Internal Medicine 1979, 139: 289-292. PMID: 106783, DOI: 10.1001/archinte.1979.03630400021012.Peer-Reviewed Original ResearchConceptsJejunoileal bypassLiver failureNutritional repletionBiopsy specimensSerial liver biopsy specimensMinimal portal fibrosisLiver biopsy specimensPostoperative biopsy specimensIntestinal reanastomosisRefractory obesityHistologic improvementMild cirrhosisParenteral nutritionPortal fibrosisProlonged courseReanastomosisBypassCirrhosisPatientsPrevious reportsRepletionNutritionFailureHypoprothrombinemiaSteatonecrosisNonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption
Levin D, Baker A, Riddell R, Rochman H, Boyer J. Nonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption. The American Journal Of Medicine 1979, 66: 429-434. PMID: 433949, DOI: 10.1016/0002-9343(79)91064-7.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseNonalcoholic liver diseaseLiver diseaseLiver biopsyHeavy alcohol consumptionAlcohol consumptionHepatitis B surface antigenSerum glutamic oxaloacetic transaminaseB surface antigenGlutamic oxaloacetic transaminaseAcute hepatitisChronic hepatitisTransaminase ratioConsecutive patientsLiver injuryAppropriate therapyClinical featuresLiver disordersOverlooked causeAlcoholic subjectsPatientsSurface antigenOxaloacetic transaminaseBiopsyDisease
1978
Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man
Schneider J, Schoeller D, Nemchausky B, Boyer J, Klein P. Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clinica Chimica Acta 1978, 84: 153-162. PMID: 639299, DOI: 10.1016/0009-8981(78)90489-8.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatic microsomal drug metabolismMicrosomal drug metabolismSimultaneous oral administrationDrug-drug interactionsNon-invasive assessmentN-demethylation activityOral doseCumulative excretionOral administrationEffects of diseaseExcretion of labelAdult subjectsDrug metabolismDiseaseExpired breathCumulative appearanceHuman subjectsPatientsReproducible increaseAminopyrineRadiation riskExcretionSubjectsHours
1974
Variation in hepatic bile composition following cholecystectomy in patients with previous gallstones.
Boyer J, Bloomer J, Maddrey W, Tilson D. Variation in hepatic bile composition following cholecystectomy in patients with previous gallstones. The Yale Journal Of Biology And Medicine 1974, 47: 211-7. PMID: 4456833, PMCID: PMC2595121.Peer-Reviewed Original ResearchConceptsHepatic bileBile compositionEnterohepatic circulationBile acidsBile acid poolLithogenicity of bileHepatic bile compositionBile specimensDay study periodT-tubeCholesterol gallstonesPatientsExcretion rateCholecystectomyBileStudy periodGallstonesAcid poolAdmirandGallbladderLithogenicityCirculation